Alisertib, TAK-228 Combo Shows Promise for Treating Triple-Negative Breast Cancer
News
New data presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, in Philadelphia, demonstrated that using alisertib along with TAK-228, two of Takeda‘s investigational therapies, was more effective in patients with ... Read more